Global Blood Therapeutics Inc.

25.57-0.9500-3.58%Vol 936.78K1Y Perf -52.05%
Sep 24th, 2021 16:00 DELAYED
BID25.57 ASK25.59
Open26.39 Previous Close26.52
Pre-Market- After-Market25.68
 - -  0.11 0.43%
Target Price
74.00 
Analyst Rating
Strong Buy 1.40
Potential %
189.40 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-33/-50 
Value Ranking
★★+     47.92
Insiders Value % 3/6/12 mo.
-/-67/-90 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-68/-87 
Income Ranking
 —    -
Price Range Ratio 52W %
0.23 
Earnings Rating
Sell
Market Cap1.60B 
Earnings Date
4th Nov 2021
Alpha0.01 Standard Deviation0.20
Beta1.00 

Today's Price Range

25.5126.75

52W Range

25.4864.49

5 Year PE Ratio Range

-15.20-18.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-8.78%
1 Month
-10.69%
3 Months
-29.83%
6 Months
-36.75%
1 Year
-52.05%
3 Years
-37.17%
5 Years
12.40%
10 Years
-

TickerPriceChg.Chg.%
GBT25.57-0.9500-3.58
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Financial StrengthValueIndustryS&P 500US Markets
6.30
7.20
0.42
0.73
-20.20
Leverage Ratio 1.70
ProfitabilityValueIndustryS&P 500US Markets
98.30
-153.90
-148.50
-
-
RevenueValueIndustryS&P 500US Markets
164.78M
2.64
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2021-1.17-1.124.27
Q01 2021-1.02-1.21-18.63
Q04 2020-0.97-1.00-3.09
Q03 2020-0.72-0.97-34.72
Q02 2020-1.18-0.8627.12
Q01 2020-1.47-1.2018.37
Q04 2019-1.22-1.73-41.80
Q03 2019-1.03-1.07-3.88
Earnings Per EndEstimateRevision %Trend
9/2021 QR-1.10-1.85Negative
12/2021 QR-1.06-1.92Negative
12/2021 FY-4.492.39Positive
12/2022 FY-3.02-5.96Negative
Next Report Date4th Nov 2021
Estimated EPS Next Report-1.10
Estimates Count14
EPS Growth Next 5 Years %-
Volume Overview
Volume936.78K
Shares Outstanding62.41M
Shares Float60.94M
Trades Count8.72K
Dollar Volume179.65M
Avg. Volume1.07M
Avg. Weekly Volume1.02M
Avg. Monthly Volume1.07M
Avg. Quarterly Volume1.33M

Global Blood Therapeutics Inc. (NASDAQ: GBT) stock closed at 25.57 per share at the end of the most recent trading day (a -3.58% change compared to the prior day closing price) with a volume of 937.68K shares and market capitalization of 1.60B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 389 people. Global Blood Therapeutics Inc. CEO is Ted W. Love.

The one-year performance of Global Blood Therapeutics Inc. stock is -52.05%, while year-to-date (YTD) performance is -40.96%. GBT stock has a five-year performance of 12.4%. Its 52-week range is between 25.48 and 64.49, which gives GBT stock a 52-week price range ratio of 0.23%

Global Blood Therapeutics Inc. currently has a PE ratio of -6.50, a price-to-book (PB) ratio of 5.54, a price-to-sale (PS) ratio of 10.26, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -38.68%, a ROC of -42.54% and a ROE of -63.46%. The company’s profit margin is -%, its EBITDA margin is -148.50%, and its revenue ttm is $164.78 Million , which makes it $2.64 revenue per share.

Of the last four earnings reports from Global Blood Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.10 for the next earnings report. Global Blood Therapeutics Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Global Blood Therapeutics Inc. is Strong Buy (1.4), with a target price of $74, which is +189.40% compared to the current price. The earnings rating for Global Blood Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Global Blood Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Global Blood Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.83, ATR14 : 1.34, CCI20 : -107.24, Chaikin Money Flow : -0.11, MACD : -0.87, Money Flow Index : 37.04, ROC : -14.77, RSI : 38.03, STOCH (14,3) : 1.10, STOCH RSI : 0.00, UO : 40.71, Williams %R : -98.90), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Global Blood Therapeutics Inc. in the last 12-months were: Brian Edwin Cathers (Option Excercise at a value of $0), David L. Johnson (Option Excercise at a value of $0), Dawn Svoronos (Option Excercise at a value of $0), Dawn Svoronos (Sold 1 609 shares of value $58 793 ), Deval L. Patrick (Option Excercise at a value of $0), Eric Fink (Buy at a value of $18 980), Eric Fink (Option Excercise at a value of $0), Eric Fink (Sold 4 532 shares of value $271 920 ), Glenn Pierce (Option Excercise at a value of $0), Jeffrey S. Farrow (Option Excercise at a value of $0), Jung E. Choi (Option Excercise at a value of $0), Mark L. Perry (Option Excercise at a value of $0), Philip A. Pizzo (Option Excercise at a value of $0), Philip A. Pizzo (Sold 1 065 shares of value $38 915 ), Scott W. Morrison (Option Excercise at a value of $0), Ted W. Love (Option Excercise at a value of $0), Tricia Borga Suvari (Option Excercise at a value of $0), Wendy L. Yarno (Option Excercise at a value of $0), Willie Brown (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
12 (80.00 %)
11 (78.57 %)
11 (78.57 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (20.00 %)
3 (21.43 %)
3 (21.43 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.43
Strong Buy
1.43

Global Blood Therapeutics Inc.

Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.

CEO: Ted W. Love

Telephone: +1 650 741-7700

Address: 171 Oyster Point Boulevard, South San Francisco 94080, CA, US

Number of employees: 389

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

52%48%

Bearish Bullish

65%35%

TipRanks News for GBT

Wed, 08 Sep 2021 12:15 GMT Analysts Top Healthcare Picks: Global Blood Therapeutics (GBT), RedHill Biopharma (RDHL)

- TipRanks. All rights reserved.

News

Stocktwits